Jefferies reiterates Buy on MercadoLibre stock, $2,600 target

Jefferies maintained its Buy rating and $2,600 price target on MercadoLibre, about 40% above the cited $1,860.61 share price, arguing that drug retail could become a strategically important GMV contributor and that free-cash-flow trends are more supportive than margin concerns suggest. In separate recent results, Q2 2026 EPS of $9.19 and revenue of $10.17 billion beat estimates of $8.75 and $9.66 billion, respectively, with revenue up 50% year over year; shares nevertheless fell after hours amid margin and investment concerns. MercadoLibre is also offering dollar notes due 2036 at an initial spread of roughly 160 basis points over comparable US Treasuries.

Analysis

The key debate is earnings quality, not demand: pharmacy could raise purchase frequency and strengthen MercadoLibre’s ecosystem, but the strategic payoff depends on whether prescription activity adds repeat transactions without structurally worsening fulfillment costs or marketplace take rates. Any benefit to payments cross-sell is a possibility, not yet demonstrated. The market’s negative reaction to a reported earnings beat suggests incremental investment and margin trajectory may matter more near term than GMV expansion.

Over the next 1–3 months, look for evidence in operating expenses, EBIT margin, and free-cash-flow conversion that separates productive investment from dilution. Treat the cited free-cash-flow yield and fair-value assessment as vendor analysis, not verified guidance or a valuation floor. The proposed long-dated dollar debt is not by itself evidence of stress; however, confirm final pricing, use of proceeds, and currency exposure before interpreting the spread as a credit signal.

Over 6–18 months, successful prescription capture could support retention and make the platform harder to displace, while regulated fulfillment and inventory obligations could consume the economics. Amazon and Sea Limited are relevant competitive reference points, but the article provides no evidence of direct market-share effects. The bullish case is falsified by continued margin deterioration without corresponding cash-flow improvement; it strengthens if repeat engagement grows while margins stabilize.

Key Decisions for Investors

• Avoid chasing the analyst target. Consider a staged long in MELI only after the next results or guidance show margin stabilization alongside resilient free cash flow; the near-term risk is further de-rating if investment intensity remains high.
• Track pharmacy-specific evidence: prescription customer growth, repeat-purchase frequency, fulfillment costs, and contribution to GMV. Until disclosed, treat the initiative as an option on engagement rather than a material earnings driver.
• Monitor final terms of the 2036 notes and subsequent credit-spread moves. A materially wider spread or evidence of rising dollar liabilities without matching cash-flow capacity would weaken the equity thesis; the initial indicated spread alone does not establish distress.
• Falsification trigger: another period of EBIT-margin pressure with weakening free-cash-flow conversion and no improvement in repeat engagement. Conversely, stabilizing margins and improving cash conversion would support adding exposure.